Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Casirivimab
Peptide
Emergency use authorization Experimental Antiviral Jan/23/2023
Imdevimab
Peptide
Emergency use authorization Experimental Antiviral Jan/23/2023
Bamlanivimab
Peptide
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
BNT162b2
Peptide
Approved by FDA Experimental Vaccine Jun/22/2022
REGEN-COV
Peptide
Emergency use authorization Experimental Antiviral Jun/03/2022
ACE2‐Fc
Peptide
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/26/2022
Tocilizumab
Peptide
Recommended by China's NHC Guidelines Used to treat other disease Other treatment Dec/21/2021
Camostat mesylate
Peptide
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Apr/22/2021
PCI-27483
Peptide
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/12/2021
Antipain
Peptide
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/12/2021
Soybean Trypsin Inhibitor
Peptide
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/12/2021
Avoralstat
Peptide
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/12/2021
Epigallocatechin Gallate
Peptide
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/08/2021
MXB-9
Peptide
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/31/2021
MXB-4
Peptide
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/31/2021
Cyclosporine
Peptide
Potential treatment - clinical evidence Used to treat other disease Other treatment Mar/23/2021
EK1C4
Peptide
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/20/2021
EK1
Peptide
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/20/2021
Nafamostat mesylate
Peptide
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/20/2021
hACE221-55A36K-F40E
Peptide
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/02/2021